United States Patent 10,525,057 (Aripiprazole Long-Acting Suspension) Claim Scope, Patent Landscape, and Generic/Biosimilar Risk

Executive summary: U.S. Patent 10,525,057 claims a narrow initiation regimen for systemic aripiprazole using an intramuscular (IM) long-acting suspension that releases aripiprazole over about one month, with dose fraction (66–75%, 53%, 50%) tied to CYP2D6/CYP3A4 metabolizer status and concomitant use of strong inhibitors. The claim set is structured to fence off at least three patient subpopulations: CYP2D6/CYP3A4 extensive with strong inhibitor coadministration, CYP2D6 poor without strong inhibitors of the specified enzymes, and a third group combining extensive status with both strong CYP2D6 and CYP3A4 inhibitors. A central composition anchor appears in dependent claims requiring a specific long-acting ester/prodrug-like molecule: (7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl dodecanoate.

What does US 10,525,057 claim about aripiprazole initiation with long-acting IM suspension and CYP2D6/CYP3A4 modifiers?

Short answer (claim theme): The patent protects methods of initiating systemic aripiprazole treatment by giving an IM long-acting suspension (monthly release) at a reduced initial fraction of a 300 or 400 mg weight-equivalent dose, where the fraction depends on genotype/phenotype (CYP2D6, CYP3A4 extensive vs poor) and coadministration of strong CYP2D6 and/or CYP3A4 inhibitors.

Claim 1: Core protected method (Extensive metabolizers + strong inhibitor coadministration)

Claim 1 requires all elements:

IM initiation of aripiprazole systemic treatment.
Initial dose is 66% to 75% of a 300 or 400 mg weight equivalent dose.
Delivered as a long-acting drug-containing suspension that systemically releases aripiprazole.
Release occurs over about one month.
Patient is CYP2D6 extensive metabolizer and CYP3A4 extensive metabolizer.
Patient is concomitantly administered a strong CYP2D6 inhibitor or a strong CYP3A4 inhibitor (at least one of the two).

This is a dosage-adjustment claim tethered to both enzyme phenotype and drug-drug interaction risk.

Claims 2–5: Fraction carve-outs within the core range

Claim 2: 66% to 75% of 300 mg weight-equivalent dose.
Claim 3: specifically 66% of 300 mg.
Claim 4: 66% to 75% of 400 mg weight-equivalent dose.
Claim 5: specifically 75% of 400 mg.

These narrow dependent claims reinforce infringement coverage for commercial dosing decisions within the broader numeric range.

Claims 6–8: Composition/prodrug anchor (specific long-acting moiety)

Claim 6: suspension comprises a prodrug of aripiprazole.
Claim 7: suspension comprises aripiprazole (not necessarily the prodrug).
Claim 8: suspension specifically comprises (7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl dodecanoate.

Dependent claims 6–8 matter for both (i) claim strength and (ii) design-around: if a competitor uses a different long-acting prodrug/long-acting moiety, it may avoid dependent claim 8, but still face independent claim 1/9/15 if the IM monthly suspension releasing aripiprazole is otherwise met.

Claim 9: CYP2D6 poor metabolizer without specified strong inhibitors

Claim 9 requires:

IM initiation of systemic aripiprazole.
Initial dose 75% of a 300 or 400 mg weight equivalent dose.
Long-acting monthly suspension releasing aripiprazole.
Patient is CYP2D6 poor metabolizer.
Patient is not concomitantly administered a strong CYP3A4 inhibitor or a strong CYP2D6 inhibitor.

This claim is essentially a guardrail for the poor metabolizer group where the clinician is not co-administering enzyme inhibitors.

Claims 10–11: Fixed-dose endpoints

Claim 10: 75% of 300 mg.
Claim 11: 75% of 400 mg.

Claims 12–14: Prodrug and specific moiety for claim 9 subgroup

Claim 12: suspension comprises a prodrug of aripiprazole.
Claim 13: suspension comprises aripiprazole.
Claim 14: suspension comprises the specific (… )methyl dodecanoate molecule.

Claim 15: Extensive metabolizers with strong CYP2D6 AND strong CYP3A4 inhibitors (dual-inhibition)

Claim 15 requires:

IM initiation.
Initial dose 53% of 300 mg or 50% of 400 mg weight-equivalent dose.
Monthly release via long-acting suspension releasing aripiprazole.
Patient is CYP2D6 extensive and CYP3A4 extensive.
Patient is concomitantly administered a strong CYP2D6 inhibitor AND a strong CYP3A4 inhibitor (dual requirement).

This claim is tighter than claim 1 because it specifies both inhibitor classes.

Claims 16–17: Numeric reinforcement for claim 15

Claim 16: 53% of 300 mg.
Claim 17: 50% of 400 mg.

Claims 18–20: Prodrug/specific moiety for claim 15

Claim 18: suspension comprises a prodrug.
Claim 19: suspension comprises aripiprazole.
Claim 20: suspension comprises the (… )methyl dodecanoate moiety.

How broad are the claims, and what specific elements narrow patent coverage in US 10,525,057?

Core breadth: The independent claims (1, 9, 15) are method-of-treatment claims. They cover:

Initiation (first dosing event implied by “initially intramuscularly administering”).
A long-acting suspension with about one month release.
Dosing is defined by explicit numeric fractions of a 300 or 400 mg weight-equivalent dose.
Patient is stratified by CYP2D6/CYP3A4 phenotype and strong inhibitor coadministration.

Primary narrowing levers:

Long-acting IM suspension with monthly systemic release.
Dose fraction tied to a specific reference dose framework (300/400 mg weight-equivalent).
Patient metabolic status: extensive vs poor.
Concomitant strong inhibitors: “strong CYP2D6 inhibitor or strong CYP3A4 inhibitor” vs “strong CYP2D6 inhibitor and strong CYP3A4 inhibitor,” and the “not concomitantly administered” limitation for claim 9.

Design-around opportunities implied by claim structure:

Avoid one or more required elements: e.g., different formulation type (not a long-acting monthly suspension), different dosing fraction, or dosing outside “initially” initiation regimen.
For composition-dependent coverage (claims 6/8/12/14/18/20), replace the specified long-acting prodrug/ester-like molecule (the methyl dodecanoate structure) with a different long-acting drug-containing suspension.

What is the dose-ranging and patient-subpopulation matrix protected by US 10,525,057?

Matrix of protected initial dosing regimens (claims 1, 9, 15)

Claim	Patient CYP status	Concomitant “strong inhibitor” condition	Long-acting monthly IM suspension requirement	Initial fraction of “300 or 400 mg weight equivalent”
Claim 1	CYP2D6 extensive AND CYP3A4 extensive	strong CYP2D6 inhibitor OR strong CYP3A4 inhibitor	required	66%–75%
Claim 9	CYP2D6 poor	NOT concomitantly administered strong CYP3A4 inhibitor OR strong CYP2D6 inhibitor	required	75%
Claim 15	CYP2D6 extensive AND CYP3A4 extensive	strong CYP2D6 inhibitor AND strong CYP3A4 inhibitor	required	53% of 300 mg OR 50% of 400 mg

Dependency coverage: The specific moiety claim (8/14/20) applies only when the suspension contains (7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl dodecanoate.

Which formulation/prodrug chemical element in US 10,525,057 affects infringement risk?

The repeated dependent limitation is a specific long-acting drug-containing suspension ingredient:

(7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl dodecanoate (claims 8, 14, 20)

Practical claim impact

If a generic or follow-on uses the same or functionally equivalent long-acting suspension containing this moiety, dependent-claim exposure increases.
If it uses a different long-acting prodrug or different aripiprazole long-acting ester, it can potentially avoid dependent-claim 8/14/20 but still risk independent-claim infringement if it meets the method elements: monthly release, IM initiation, systemic release of aripiprazole, and the enzyme/inhibitor-adjusted dose fraction.

How strong is the patent estate for method-of-use vs composition coverage in US 10,525,057?

Method-of-use strength: High leverage for enforcement against prescribing and administration workflows, because the method claims require exact clinical facts: metabolizer phenotype and concomitant strong inhibitor status.

Composition anchor strength: Medium to high for formulation competitors because dependent claims can narrow to a particular prodrug moiety. But composition coverage is not claimed directly here; this patent is framed as a method of initiating treatment, with the composition/prodrug appearing inside the method via the “suspension comprises” limitations.

What generic entry risks exist under Hatch-Waxman for methods like those in US 10,525,057?

Key litigation risk vector

A generic program that seeks FDA approval for a long-acting aripiprazole IM suspension would typically aim to claim a comparable formulation and then rely on label indications/dosing language.

The patent is not a composition patent on its face in the claim excerpt. It is a method claim. That creates a typical risk profile:

If the proposed label and prescribing instructions include the claimed initiation fractions for the relevant CYP-inhibitor patient groups and the product can be used as claimed, the claimant may pursue induced/contributory infringement theories (fact-dependent and jurisdiction-dependent).
If the generic label omits those specific fraction/initiation instructions or contraindicates the claimed scenario, litigation still can arise based on off-label practice and “use” of the method.

Numerical-fraction specificity is a double-edged sword

It narrows what is needed to infringe the method.
It also makes it easier to argue non-infringement if the generic uses different starting fractions or a different titration approach.

What biosimilar risk applies to US 10,525,057?

This is not a biologic claim. It is a small-molecule aripiprazole long-acting suspension method. There is no biosimilar framework risk to map directly here.

How does US 10,525,057 compare with typical aripiprazole long-acting patent strategies?

Most aripiprazole long-acting patent landscapes concentrate on:

Formulation and long-acting prodrug moieties
Manufacturing and particle engineering
Dosing regimens and loading approaches

US 10,525,057 is distinct because the claims tie initiation dosing fractions to:

CYP2D6/CYP3A4 metabolizer phenotype, and
presence/absence of strong inhibitors (and whether it is single-inhibitor vs dual-inhibitor situations).

That yields a clinical personalization overlay that can reduce claim overlap with more generic “one-size” dosing patents.

What enforcement and licensing hooks follow from the claim structure of US 10,525,057?

Labeling/PI carve-outs: Any licensing discussions will focus on whether the initiation instructions in a label match the claimed fractions and the specified enzyme/inhibitor strata.
Clinical workflow control: Enforcement can focus on prescriber behavior and administration in the claimed patient populations.
Formulation differentiation: If the licensing party can use a different long-acting moiety, it may attempt to avoid dependent claim coverage tied to the methyl dodecanoate moiety, while still requiring assessment against the independent method elements.

What can be concluded about the geographic scope from the patent number alone?

US 10,525,057 is a United States patent. The enforceable scope is the U.S. territory. International licensing would depend on whether corresponding families exist, which is outside the claim text provided.

Key Takeaways

US 10,525,057 protects initiation methods for systemic aripiprazole using an IM long-acting suspension with about one-month release, with initial dosing fractions tightly defined.
Claims are built around CYP2D6/CYP3A4 phenotype and strong inhibitor coadministration:
- Extensive/extensive with strong CYP2D6 or strong CYP3A4 inhibitor: 66%–75%
- CYP2D6 poor without strong inhibitors: 75%
- Extensive/extensive with strong CYP2D6 AND strong CYP3A4 inhibitors: 53% (300 mg) or 50% (400 mg)
Dependent claims add a specific long-acting moiety: (… )methyl dodecanoate, which can be a formulation differentiation lever.
Generic entry risk is highest where a follow-on product and label enable prescribers to initiate treatment using the claimed fractions in the claimed CYP/inhibitor subpopulations.

FAQs

1) Does US 10,525,057 require a specific duration of release other than “about one month”?
Yes. The method requires systemic release of aripiprazole over about one month as part of the long-acting suspension limitation.

2) Are both 300 mg and 400 mg dose references required in each claim?
No. Claims use “300 or 400 mg weight equivalent dose.” Dependent claims specify either 300 or 400 with the associated fraction.

3) What is the difference between claim 1 and claim 15 regarding inhibitors?
Claim 1 allows concomitant administration of a strong CYP2D6 inhibitor or a strong CYP3A4 inhibitor (either/or). Claim 15 requires both a strong CYP2D6 inhibitor and a strong CYP3A4 inhibitor.

4) Is the specific prodrug moiety required for the independent claims?
No. The independent claims require a long-acting suspension that systemically releases aripiprazole; the exact (… )methyl dodecanoate appears in dependent claims.

5) Can a product avoid the patent by changing only the initial fraction?
If the fraction falls outside the claimed ranges and fixed endpoints, it can avoid meeting the method’s numeric limitations, assuming all other elements are not met.

References

No sources were provided beyond the claim text in the prompt, and no external patent record details were included here.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-001	Feb 28, 2013		RX	Yes	No	10,525,057	⤷ Start Trial				TREATMENT OF SCHIZOPHRENIA	⤷ Start Trial
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-001	Feb 28, 2013		RX	Yes	No	10,525,057	⤷ Start Trial				TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA	⤷ Start Trial
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-001	Feb 28, 2013		RX	Yes	No	10,525,057	⤷ Start Trial				MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR 1 DISORDER	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Details for Patent: 10,525,057

Which drugs does patent 10,525,057 protect, and when does it expire?

Summary for Patent: 10,525,057